Polyunsaturated fatty acids and renal fibrosis: Pathophysiologic link and potential clinical implications

Journal of Nephrology

Volumn 18, Issue 4, 2005, Pages 362-367

  Baggio, Bruno ^a,b   Musacchio, Estella ^a   Priante, Giovanna ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Chronic kidney disease progression; Polyunsaturated fatty acids; Renal fibrosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSANOID; LIPID; NITRIC OXIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; RENIN; SCLEROPROTEIN;

ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; FAT INTAKE; GENE EXPRESSION; HUMAN; KIDNEY FIBROSIS; LIPID BLOOD LEVEL; MESANGIUM CELL; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PLEIOTROPY; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

ANIMALS; CELL PROLIFERATION; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FATTY ACIDS, UNSATURATED; FIBROSIS; GLOMERULAR MESANGIUM; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 28244453362     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004; 13: 279-84.
2. Gross ML, Amann K. Progression of renal disease: new insights into risk factors and pathomechanisms. Curr Opin Nephrol Hypertens 2004; 13: 307-12.
3. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-8.
4. Baggio B. Ischemic renal disease: impact of cardiovascular risk factors and smoking. Contrib Nephrol 2000; 130: 68-74.
5. Diamond JR. Analogous pathobiologic mechanism in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991; 39: S29-34.
6. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney disease: causes or consequences. Curr Opin Nephrol Hypertens 2002; 11: 323-9.
7. Keane WF. Lipids in the kidney. Kidney Int 1994; 46: 910-20.
8. Mantarri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995; 26: 670-5.
9. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-91.
10. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-11.
11. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991; 17 (suppl 1): S38-42.
12. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9.
13. Ruan XZ, Varghese Z, Moorhead JF. Inflammation modifies lipid-mediated renal injury. Nephrol Dial Transplant 2003; 18: 27-32.
14. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990; 37: 880-91.
15. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995; 26: 152-62.
16. Kasiske BL, O'Donnell MP, Kim Y, Atluru D, Keane WF. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. Kidney Int Suppl 1994; 45: S51-3.
17. Keane WF, Kasiske BL, O'Donnel MP, Schmitz PG. Therapeutic implications of lipid-lowering agents in the progression of renal disease. Am J Med 1989; 87: 21-4N.
18. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduce glomerular injury in Dahl salt-sensitive rats. Hypertension 1992; 20: 651-8.
19. O'Donnell MP, Kasiske BL, Schmitz PG, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993; 22: 83-9.
20. Guijarro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A- reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 1996; 22: 147-52.
21. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002; 61: 1635-45.
22. Afzali B, Haydar AA, Vinen K, Goldsmith DJ. Beneficial effects of statins on the kidney: the evidence moves from mouse to man. Nephrol Dial Transplant 2004; 19: 1032-6.
23. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-70.
24. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.
25. Corsini A. Fluvastatin: effects beyond cholesterol lowering. J Cardiovasc Pharmacol Ther 2000; 5: 161-75.
26. Mueck AO, Seeger H, Wallwiener D. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes 2001; 109: 181-3.
27. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephritic rats. Am J Kidney Dis 1998; 31: 1904.
28. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993; 91: 83-7.
29. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1; modulation by lovastatin. Kidney Int 1995; 48: 363-71.
30. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WE, Kashtan CE. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant 1996; 11: 990-6.
31. Das UN. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 37-40.
32. Kasiske BL, O'Donnell MP, Lee H, Kim Y, Keane WF. Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats. Kidney Int 1991; 39: 1125-34.
33. Schmitz PG, O'Donnell MP, Kasiske BL, Keane WF. Glomerular hemodynamic effects of dietary polyunsaturated fatty acid supplementation. J Lab Clin Med 1991; 118: 129-35.
34. Rise P, Ghezzi S, Galli C. Relative potencies of statins in reducing cholesterol synthesis and enhancing linoleic acid metabolism. Eur J Pharmacol 2003; 467: 73-5.
35. Harris JI, Hibbeln JR, Mackey RH, Muldoon MF. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 263-9.
36. Laidlaw M, Holub BJ. Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women. Am J Clin Nutr 2003; 77: 37-42.
37. Hamazaki K, Itomura M, Huan M, Nishizawa H, Watanabe S, Hamazaki T, Sawazaki S, Terasawa IT, Nakajima S, Terano T, Hata Y, Fujishiro S. n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans. Lipids 2003; 38: 353-8.
38. Theobald HE, Chowienczyk PJ, Whittall R, Humphries SE, Sanders TA. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr 2004; 79: 558-63.
39. Nakamura MT, Nara TY. Structure, function, and dietary regulation of delta 6, delta 5, and delta 9 desaturases. Annu Rev Nutr 2004; 24: 345-76.
40. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71 (Suppl): S343-8.
41. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 2001; 36: 1007-24.
42. Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2093; 38: 343-52.
43. Ingram AJ, Parbtani A, Clark WE Spanner E, Huff MW, Philbrick DJ, Holub BJ, Scholey JW. Dietary alteration of dihomogammalinolenic acid/arachidonic acid ratio in a rat 5/6-renal-ablation model. J Am Soc Nephrol 1996; 7: 1024-31.
44. Wheeler DC, Nair DR, Persaud JW, Jeremy JY, Chappell ME, Varghese Z, Moorhead JF. Effects of dietary fatty acids in an animal of focal glomerulosclerosis. Kidney Int 1991; 39: 930-7.
45. Chandrasekar B, Fernades G. Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by omega-3 lipids in murine lupus nephrithis. Biochem Biophysic Res Commun 1994; 200: 893-8.
46. Goldstein DJ, Wheeler DC, Sandstrom DJ, Kawachi H, Salant DJ. Fish oil ameliorates renal injury and hyperlipidemia in the Milan normotensive rat model of focal glomerulosclerosis. J Am Soc Nephrol 1995; 6: 1468-75.
47. Ogborn MR, Nitschmann E, Weiler H, Leswick D, Bankovic-Calic N. Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease. Kidney Int 1999; 55: 417-23.
48. Ogborn MR, Nitschmann E, Bankovic-Calic N, Weiler HA, Fitzpatrick-Wong S, Aukema HM. Dietary conjugated linoleic acid reduces PGE2 release and interstitial injury in rat polycystic kidney disease. Kidney Int 2003; 64: 1214-21.
49. Brown SA, Brown CA, Crowell WA, Barsanti JA, Allen T, Cowell C, Finco DR. Beneficial effects of chronic administration of dietary omega-3 polyunsaturated fatty acids in dogs with renal insufficiency. J Lab Clin Med 1998; 131: 447-55.
50. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-48.
51. Miyazaki M, Takemura N, Watanabe S, Hata N, Misawa Y, Okuyama H. Dietary docosahexaenoic acid ameliorates, but rapeseed oil and safflower oil accelerate renal injury in stroke-prone spontaneously hypertensive rats as compared with soybean oil, which is associated with expression for renal transforming growth factor-beta, fibronectin and renin. Biochim Bioph Acta 2000; 1483: 101-10.
52. Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr 2004; 58: 195-203.
53. Ng R. Fish oil therapy in recurrent IgA nephropathy. Ann Intern Med 2003; 138: 1011-2.
54. Tsipas G, Morphake P. Beneficial effects of a diet rich in a mixture of n-6/n-3 essential fatty acids and of their metabolites on cyclosporine-nephrotoxicity. J Nutr Bioch 2003; 14: 626-32.
55. Theuer J, Shagdarsuren E, Muller DN, Kaergel E, Honeck H, Park JK, Fiebeler A, Dechend R, Haller H, Luft FC, Schnuck WH. Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage. Kidney Int 2005; 67: 248-58.
56. Noronha IL, Fujiliara CK, Zatz R. The inflammatory component in progressive renal disease - are interventions possible? Nephrol Dial Transplant 2002; 17: 363-8.
57. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881-900.
58. Graber R, Sumuda C, Nunez EA. Fatty acids and cell signal transduction. J Lipid Mediat Cell Signal 1994; 9: 91-116.
59. Di Marzo V. Arachidonic acid and eicosaoids as targets and effectors in second messenger interactions. Prostglandins Leukot Essent Fatty Acids 1995; 53: 239-54.
60. Nitta K, Uchida K, Tsutsui T, Honda K, Kawashima A, Yumura W, Nihei H. Eicosapentaenoic acid inhibits mitogen-induced endothelin-1 production and DNA synthesis in cultured bovine mesangial cells. Am J Nephrol 1998; 18: 164-70.
61. Schmitz PG, Zhang K, Dalal R. Eicosapentaenoic acid suppresses PDGF-induced DNA synthesis in rat mesangial cells: involvement of thromboxane A2. Kidney Int 2000; 57: 1041-51.
62. Hida M, Fujita H, Ishikura K, Omori S, Hoshiya M, Awazu M. Eicosapentaenoic acid inhibits PDGF-induced mitognesis and cyclin D1 expression via TGF-beta in mesangial cells. J Cell Physiol 2003; 196: 2913-300.
63. Grande JP, Walker HJ, Holub BJ, Warner GM, Keller DM, Haugen JD, Donadio JV Jr, Dousa TP. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 2000; 57: 1027-40.
64. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis 1997; 30: 311-33.
65. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-9.
66. Ca channels to angiotensin II. Am J Physiol 1998; 24: F658-64.
67. Kielar ML, Jeyarajah DR, Zhou XJ, Lu CY. Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. J Am Soc Nephrol 2003; 14: 389-96.
68. Das UN, Mohan IK, Raju TR. Effect of corticosteroids and cicosapentaenoic acid/docosahexaenoic acid on pro-oxidant and anti-oxidant status and metabolism of essential fatty acids in patients with glomerular disorder. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 197-203.
69. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30.
70. Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M, Fujishima M. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys; Acta 2000; 1497: 148-54.
71. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AG. PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003; 64: 52-62.
72. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukinlbeta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 2003; 14: 593-600.
73. Priante G, Bordin L, Musacchio E, Clari G, Baggio B. Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid. Clin Sci (Lond) 2002; 102: 403-9.
74. Bordin L, Priante G, Musacchio E, Giunco S, Tibaldi E, Clari G, Baggio B. Arachidonic acid-induced IL-6 expression is mediated by PKC alpha in osteoblastic cells. Biochemistry 2003; 42: 4485-91.
75. Priante G, Musacchio E, Pagnin E, Calo LA, Baggio B. Specific effect of arachidonic acid on inducible nitric oxide synthase (iNOS) mRNA expression in human osteoblastic cells. Clin Sci (Lond) 2005; 109: 177-82.
76. Kamanna VS, Bassa BV, Vaziri ND, Roh DD. Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kidney Int Suppl 1999; 56: S70-5.
77. Alexander LD, Cui XL, Falck JR, Douglas JG. Arachidonic acid directly activates members of the mitogen-activated protein kinase superfamily in rabbit proximal tubular cells. Kidney Int 2001; 59: 2039-53.
78. Baggio B. Fatty acids, calcium and bone metabolism. J Nephrol 2002; 15: 601-4.
79. Brenner RR. Factors influencing fatty acid chain elongation and desaturation. In Vergrossen AJ, Crawford M eds. The role of fats in human nutrition. London: Academic Press 1989; 45-9.
80. Gambaro G, Bordoni A, Hrelia S, Bordin L, Biagi P, Semplicini A, Clari G, Manzato E, Baggio B. Dietary manipulation of delta-6 desaturase modifies phospholipid arachidonic acid levels and the urinary excretion of calcium and oxalate in the rat: insight in calcium lithogenesis. J Lab Clin Med 2000; 135: 89-95.
81. Baggio B, Budakovic A, Nassuato MA, Vezzoli G, Manzato E, Luisetto G, Zaninotto M. Plasma phospholipid arachidonic acid content and calcium metabolism in idiopathic calcium nephrolithiasis. Kidney Int 2000; 58: 1278-84